Jesus, Suzana Marques dePinto, Leonardo Santos RibeiroMoreira, Fernanda de LimaNardotto, Glauco Henrique BalthazarCristofoletti, RodrigoMelo, Luísa Helena Perin deFonseca, Kátia da SilvaBarbêdo, PaulianaBandeira, Lorena CeraVieira, Paula Melo de AbreuCarneiro, Cláudia Martins2022-04-052022-04-052021JESUS, S. M. de et al. Pharmacokinetics of Benznidazole in experimental chronic Chagas Disease using the Swiss mouse-Berenice-78 Trypanosoma cruzi strain model. Antimicrobial Agents and Chemotherapy, v. 65, artigo e01383-20, fev. 2021. Disponível em: <https://journals.asm.org/doi/10.1128/AAC.01383-20?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed>. Acesso em: 10 jun. 2021.1098-6596http://www.repositorio.ufop.br/jspui/handle/123456789/14841Chronic Chagas disease might have an impact on benznidazole pharmacokinetics with potential alterations in the therapeutic dosing regimen. This study aims to investigate the influence of chronic Trypanosoma cruzi infection on the pharmacokinetics and biodistribution of benznidazole in mice. Healthy (n= 40) and chronically T. cruzi (Berenice-78 strain)-infected (n= 40) Swiss female 10-month-old mice received a single oral dose of 100 mg/kg of body weight of benznidazole. Serial blood, heart, colon, and brain samples were collected up to 12 h after benznidazole administration. The serum and tissue samples were analyzed using a high-performance liquid chromatography instrument coupled to a diode array detector. Chronic infection by T. cruzi increased the values of the pharmacokinetic parameters absorption rate constant (Ka) (3.92 versus 1.82 h21 ), apparent volume of distribution (V/F) (0.089 versus 0.036 liters), and apparent clearance (CL/F) (0.030 versus 0.011 liters/h) and reduced the values of the time to the maximum concentration of drug in serum (Tmax) (0.67 versus 1.17 h) and absorption half-life (t1/2a) (0.18 versus 0.38 h). Tissue exposure (area under the concentration-versus-time curve from 0 h to time t for tissue [AUC0–t,tissue]) was longer and higher in the colon (8.15 versus 21.21mg · h/g) and heart (5.72 versus 13.58mg · h/g) of chronically infected mice. Chronic infection also increased the benznidazole tissue penetration ratios (AUC0–t,tissue/AUC0–t,serum ratios) of brain, colon, and heart by 1.6-, 3.25-, and 3-fold, respectively. The experimental chronic Chagas disease inflammationmediated changes in the regulation of membrane transporters probably influence the benznidazole pharmacokinetics and the extent of benznidazole exposure in tissues. These results advise for potential alterations in benznidazole pharmacokinetics in chronic Chagas disease patients with possibilities of changes in the standard dosing regimen.en-USrestritoPreclinical drug studiesArtigo publicado em periodicohttps://journals.asm.org/doi/10.1128/AAC.01383-20?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedhttps://doi.org/10.1128/AAC.01383-20